GDTC
GDTC
NASDAQ · Biotechnology

Cytomed Therapeutics Ltd

$1.00
-0.02 (-1.96%)
As of Jun 29, 10:38 PM ET ·
Financial Highlights (FY 2026)
Revenue
330.1K
Net Income
-4,044,463
Gross Margin
95.2%
Profit Margin
-1,227.1%
Rev Growth
D/E Ratio
0.07
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 95.2% 48.2% 48.2% 48.2%
Operating Margin -1,231.9% -13.7% -13.7% -16.6%
Profit Margin -1,227.1% -13.7% -12.0% -16.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 330.1K 1.99M 1.82M 1.81M
Gross Profit 314.4K 960.7K 880.3K 874.9K
Operating Income -4,067,110 -272,039 -249,417 -301,800
Net Income -4,044,463 -271,887 -219,394 -295,477
Gross Margin 95.2% 48.2% 48.2% 48.2%
Operating Margin -1,231.9% -13.7% -13.7% -16.6%
Profit Margin -1,227.1% -13.7% -12.0% -16.3%
Rev Growth +6.4% +1.5% -4.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 414.2K 2.19M 1.92M 2.35M
Total Equity 5.62M 8.12M 8.19M 8.32M
D/E Ratio 0.07 0.27 0.23 0.28
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -3,651,612 -443,981 -374,843 -381,153
Free Cash Flow -242,138 -341,295 -221,285